Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Chinese Academy of Medical Sciences & Peking Union Medical College Institute of Medicinal Biotechnology, Beijing 100050, China.
Can J Gastroenterol Hepatol. 2023 Mar 8;2023:8370262. doi: 10.1155/2023/8370262. eCollection 2023.
The purpose of the current study was to determine whether there is a difference between high levels of microsatellite instability (MSI-H) and microsatellite stability (MSS) in DNA mismatch repair-deficient (DMMR) colorectal cancer (CRC) patients.
A total of 452 CRC patients with DMMR from December, 2014, to April, 2021, in our hospital were selected retrospectively. However, only 105 patients underwent Sanger or next-generation-sequencing (NGS) to confirm their microsatellite status. Ultimately, 55 MSI-H patients and 20 MSS patients with intact medical record information were included in this study.
The MSS group was associated with a higher mutation rate in the KRAS gene (=0.011). Meanwhile, MSI-H was related to colon cancer ( < 0.01). However, no significant differences in other clinical characteristics were observed between the two groups of patients. There was no significant difference between the MSI-H and MSS groups in terms of overall survival (OS) (=0.398) and disease-free survival (DFS) (=0.307).
The MSI-H status was associated with colon cancer and a lower mutation rate of the KRAS gene in DMMR patients. In CRC-DMMR patients, the MSS group exhibited better OS and DFS than the MSI-H group, although these differences were not statistically significant. Accordingly, in clinical practice, we should not confuse these two types of patients.
本研究旨在确定 DNA 错配修复缺陷(DMMR)结直肠癌(CRC)患者中高度微卫星不稳定(MSI-H)与微卫星稳定(MSS)是否存在差异。
回顾性选取 2014 年 12 月至 2021 年 4 月我院收治的 452 例 DMMR CRC 患者,然而仅有 105 例行 Sanger 或下一代测序(NGS)以明确其微卫星状态。最终,本研究纳入了 55 例 MSI-H 患者和 20 例 MSS 患者,且均有完整的病历资料。
MSS 组 KRAS 基因突变率较高(=0.011)。MSI-H 与结肠癌相关(<0.01)。然而,两组患者的其他临床特征无显著差异。MSI-H 组与 MSS 组在总生存(OS)(=0.398)和无病生存(DFS)(=0.307)方面无显著差异。
MSI-H 状态与 DMMR 患者的结肠癌和 KRAS 基因突变率较低相关。在 CRC-DMMR 患者中,MSS 组的 OS 和 DFS 优于 MSI-H 组,但差异无统计学意义。因此,在临床实践中,我们不应混淆这两种类型的患者。